J&J Medical Connect
Oncology
Oncology

Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination With Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma: Updated Safety and Efficacy Results From the Phase 1b MonumenTAL-2 Study